MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
+0.060
+2.64%
Opening 14:58 11/21 EST
OPEN
2.240
PREV CLOSE
2.270
HIGH
2.340
LOW
2.190
VOLUME
1.49M
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
2.190
MARKET CAP
149.56M
P/E (TTM)
-11.2073
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AFMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AFMD News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.7h ago
  • Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.2d ago
  • Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates
  • Zacks.2d ago
  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
-0.47%
Pharmaceuticals & Medical Research
+0.28%

Hot Stocks

Name
Price
%Change

About AFMD

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
More

Webull offers Affimed NV (AFMD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.